[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:small-intestinal-adenocarcinoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":35,"states":36},"Small Intestinal Adenocarcinoma",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06835387","Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors",[11],"Phase 2","RECRUITING","2026-08-26T02:16:54.044282Z","2026-07-30T01:46:14.415011Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07417488","GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas",[19],"Phase 1","2026-08-26T02:16:01.079019Z","2026-05-13T02:55:06.703593Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT04205968","Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers",[11],"2026-08-26T02:17:55.355429Z","2026-04-29T02:57:57.082947Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT05674825","Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses",[32],"Phase 1\u002FPhase 2","2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.840688Z",[],[]]